A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Peplin
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Must be male or female and at least 18 years of age.
Female patients must be of:
Non-childbearing potential;
Childbearing potential, provided negative serum and urine pregnancy test and using effective contraception.
4 to 8 AK lesions on non-head locations.
You may not be if
Cosmetic or therapeutic procedures within 2 weeks and within 2 cm of the selected treatment area.
Treatment with immunomodulators, or interferon/ interferon inducers or systemic medications that suppress the immune system within 4 weeks.
Treatment with 5-FU, imiquimod, diclofenac, or photodynamic therapy within 8 weeks and 2 cm of treatment area
Clareo Health | A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations
